Skin ageing is increasingly recognised as a biologically driven process involving progressive dysregulation of the dermal microenvironment, rather than simply the accumulation of surface-level structural changes. Chronic low-grade inflammation, oxidative stress, reduced fibroblast metabolic activity and degradation of the extracellular matrix (ECM) contribute to declining hydration, elasticity, luminosity and overall skin resilience.1-4 

In response, biorestoration strategies that aim to restore dermal function rather than correct isolated surface features have gained clinical relevance.5 Clinical research evaluating Celora Vita™ has demonstrated histological, instrumental and clinical findings consistent with increased fibroblast activity, collagen type III production, angiogenesis, epidermis thickness leading to improved hydration, radiance, firmness and texture as well as significant improvement in fine lines and wrinkles.6-8 

Biological properties of Celora Vita™ and their role in skin renewal  

Celora Vita™ is positioned as a substrate-based biorestorative  injectable, combining a defined complex of nine amino acids and low-molecular-weight hyaluronic acid to support dermal biology rather than induce volumisation.5 This approach reflects an evolving understanding of skin ageing as a process driven by progressive impairment of fibroblast function, ECM turnover, hydration regulation and, importantly, substrate depletion.1,4,9 

Amino acids act as essential substrates for collagen, elastin and keratin synthesis.10-12 With increasing age, amino-acid availability within the dermis declines, becoming a limiting factor for effective ECM renewal even when fibroblasts remain viable.4,9,13 This substrate deficiency is particularly relevant in chronically inflamed or photoaged skin, where protein turnover is increased and regenerative demand exceeds supply or when lifestyle factors have an impact; such as poor nutrition.14 

The amino acid complex within Celora Vita™ is designed to supply substrates relevant to collagen synthesis, fibroblast metabolism and epidermal support.9,10 While fibroblasts retain regenerative potential with age, reduced availability of key amino acids can limit effective extracellular matrix (ECM) renewal.4,9,13 

Structural amino acids such as glycine and proline are fundamental to collagen triple-helix formation and stability, comprising a substantial proportion of dermal collagen content.10 Lysine plays an essential role in collagen cross-linking and matrix maturation, contributing to tensile strength and dermal integrity.15,16 

Branched-chain amino acids including leucine, isoleucine and valine support cellular protein synthesis and metabolic activity, influencing fibroblast function and tissue repair capacity.17 Their relevance may increase with age, as protein synthesis efficiency declines despite the presence of viable fibroblast populations.13 

Amino acids such as alanine and serine contribute to epidermal metabolism and hydration through their role in natural moisturising factor (NMF) composition and barrier support.18,19 Cysteine, a sulphur-containing amino acid, contributes to redox balance and keratin synthesis and plays a role in protecting cells from oxidative stress – an important consideration in environmentally stressed or inflamed skin.3,12 

Alongside amino acids, low-molecular-weight hyaluronic acid plays a key role in optimising the dermal microenvironment.20 In contrast to high-molecular-weight hyaluronic acid, which primarily provides viscoelastic support, lower-molecular-weight fragments are more biologically active within the dermis.21 These fragments are able to distribute more readily throughout the ECM and interact with fibroblast surface receptors such as CD44, influencing cellular signalling pathways involved in matrix remodelling, hydration balance and tissue repair.22 

By delivering a defined combination of these amino acids directly into the dermis, Celora Vita™ aims to support fibroblast activity and ECM synthesis by addressing substrate limitation, particularly when combined with low-molecular-weight hyaluronic acid to optimise the dermal microenvironment.9,20 

Translating mechanism into patient selection  

The substrate-based mechanism of Celora Vita™ has clear implications for patient selection and treatment positioning. Because its effects are mediated through optimisation of fibroblast activity, ECM renewal and hydration regulation – rather than volumisation or structural correction – clinical benefit is most evident in patients where skin quality decline reflects biological fatigue rather than architectural loss.1,18 

In clinical practice, this includes patients presenting with marked dehydration and dull or fatigued skin, where impaired dermal hydration regulation contributes to reduced luminosity and resilience.18 It is also well suited to patients with fine lines associated with dermal thinning and ECM exhaustion, particularly where volume loss or dynamic muscle activity is not the dominant driver of ageing.23 As well as this, Celora Vita™ is appropriate for patients with uneven tone or texture, and early to moderate chrono/photoageing.14 

The formulation also lends itself to early intervention and prejuvenation strategies, where the aim is to preserve dermal quality and delay progression of visible ageing.14 Delicate anatomical areas, such as the periocular region, may particularly benefit from this approach, as ECM support can be improved without introducing volume in tissues where volumisation is undesirable.23 

Understanding Celora Vita™ as a biorestorative solution rather than corrective intervention is essential for appropriate expectation management. Improvements typically develop progressively over weeks to months, in line with known biological timelines for ECM remodelling and fibroblast-mediated repair, rather than producing immediate structural change.1,4 

Treatment protocol

Case studies  

The following cases are drawn from my early clinical experience with Celora Vita™, in which I was involved in both case evaluation and protocol development, and are presented to illustrate clinical application in patients selected in line with the biological rationale and clinical research outlined earlier in this article. 

Patient 1: skin biorestoration in dehydrated, inflamed skin 

Patient presentation: The patient presented with moderate skin ageing characterised by marked dehydration, dull and fatigued appearance, fine lines and wrinkles, uneven skin texture and reduced firmness and elasticity. Clinical assessment suggested features of both photoageing and chronoageing, alongside background inflammation and oxidative stress. Overall, the presentation was consistent with impaired dermal function and extracellular matrix fatigue rather than isolated volume loss or dynamic line formation. 

Treatment rationale: Based on the substrate-based mechanism of Celora Vita™, a biorestorative approach was selected to support complete ECM renewal and the dermal environment.5 

Clinical observations: An early improvement in skin luminosity was observed following the first treatment session, with visible improvement noted at the two-week review. Over the course of the treatment protocol, progressive improvements were observed in skin brightness, smoothness and overall texture. 

A reduction in background erythema was also noted, suggesting improved dermal balance. Subjectively, the patient reported positive feedback from others regarding overall skin appearance, consistent with global improvement in skin quality rather than change in a single isolated feature. 

Patient 2: skin biorestoration in periocular ECM fatigue  

Patient presentation: The patient presented primarily with fine lines and wrinkles in the periocular region. Baseline skin hydration was good, but there was evidence of mild erythema and pigmentation irregularities. Botulinum toxin treatment was not considered appropriate due to the patient’s brow position. Despite adequate hydration, clinical assessment suggested localised ECM fatigue and reduced dermal support, particularly within the thin periocular skin. 

Treatment rationale:  In this case, Celora Vita™ was selected to address matrix quality rather than hydration alone. Age-related reductions in amino-acid availability and fibroblast efficiency can limit effective collagen synthesis even in well-hydrated skin, contributing to persistent fine lines in delicate anatomical areas.4,9 

The substrate-based mechanism of Celora Vita™ offered a means of supporting fibroblast activity and dermal structure without introducing volume in a region where volumisation would be undesirable. 

Clinical observations: Early improvement was observed following the first treatment session, most notably in the periocular region. Over subsequent weeks, progressive softening of fine lines and improvement in skin smoothness were noted. 

Subtle reductions in background redness and mild pigmentation irregularities were also observed. Improvement in forehead lines was limited, reinforcing the importance of appropriate indication selection and realistic expectation management when using biorestorative treatments. 

Conclusion  

The clinical research and early practice experience demonstrate that Celora Vita™, a substrate-based biorestoration injectable combining amino acids and low-molecular-weight hyaluronic acid, can support improvements in skin quality by addressing underlying biological contributors to ageing such as substrate deficiency and impaired dermal microenvironment dynamics. 

The cases presented illustrate how visible responses to Celora Vita™ may vary according to baseline skin condition and regional tissue characteristics, with changes becoming apparent over time in line with biological remodelling rather than immediate correction. These observations reinforce the importance of patient selection, expectation management and interpretation of outcomes within a regenerative, non-volumising treatment framework. 

Ongoing clinical evaluation will continue to inform best practice for the use of Celora Vita™, helping to define its role within regenerative approaches to skin quality management. 

This advertorial us published in association with DermaFocus – the manufacturer of Celora Vita™. Click here to find out more.